Therma Bright Inc.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.

Recent News

  • Therma Bright Reports Improved Accuracy For Its COVID-19 Rapid Saliva Antigen Test, CoviSafeTM, And Prepares For Prospective Studies

    Toronto, Ontario--(Newsfile Corp. - January 18, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that the most recent results achieved with nanoComposix using banked human saliva samples and utilizing a CoviSafe™ prototype device indicate a test sensitivity of 86% and a specificity of 100% for Therma's CoviSafe™ rapid antigen test for detecting SARS-CoV-2 virus in saliva. As previously reported on December 7, 2020 preliminary results achieved during...

    2021-01-18 4:00 PM ET
  • Therma Bright Adds Veteran Manufacturing Expert to Advisory Team to Advance its Saliva-Based Rapid Antigen Test CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - January 15, 2021) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the appointment of Ian Levine to the advisory board to assist with future scaling for the manufacture of CoviSafe™.Mr. Levine will build the overall operations for the Therma Bright team to secure efficient and smooth delivery of CoviSafe™ to our global customers. Mr. Levine's experience in global manufacturing and distribution of regulated...

    2021-01-15 6:30 AM ET
  • Therma Bright Signs IR Agreement with Barwicki Investor Relations, Adds $300,000 to Treasury Through Exercise of Warrants and Options; and Grants Options

    Toronto, Ontario--(Newsfile Corp. - December 24, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, announces that it has engaged Barwicki Investor Relations to provide investor relations services to the Company. Founded by Andrew Barwicki in 2006, Barwicki Investor Relations is a full service investor relations firm representing publicly traded companies and pre-IPO companies. Andrew Barwicki has 25+ years experience in finance, investor relations, investment banking and marketing. Mr....

    2020-12-24 6:39 AM ET
  • Therma Bright Achieves High Accuracy Results from Feasibility Studies for Its COVID-19 Rapid Saliva Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - December 7, 2020) -  Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce the preliminary results achieved during the feasibility studies indicate a test sensitivity of 80% and a specificity of over 90% for Therma's CoviSafe™ rapid test for detecting SARS-CoV-2 in saliva. Therma entered into an agreement with nanoComposix, a developer and manufacturer of rapid diagnostic tests to perform feasibility studies with a short...

    2020-12-07 5:07 PM ET
  • Therma Bright gründet neues Unternehmen namens Torion Biosciences zur Entwicklung seines COVID-19 Antigen-Schnelltests, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - Donnerstag, 5. November 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, gibt die Gründung eines neuen Unternehmens mit dem Namen Torion Biosciences Inc. ("Torion") bekannt, das der Entwicklung, Lizenzierung und Vermarktung eines Antigen-Schnelltests zum Screening symptomatischer sowie asymptomatischer COVID-19-Infizierter bzw. -Verdachtspersonen dienen soll. Therma Bright wird 50 % von Torion kontrollieren, während die restlichen 50 % von anderen kontrolliert werden, darunter eine Reihe erfahrener Biotech-Führungskräfte als Hauptaktionäre von...

    2020-11-05 4:18 PM ET
  • Therma Bright Creates New Venture, Torion Biosciences to Develop its COVID-19 Rapid Antigen Test, CoviSafe(TM)

    Toronto, Ontario--(Newsfile Corp. - November 4, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has created a new venture, called Torion Biosciences Inc. ("Torion") with a mandate to develop, license and commercialize a rapid antigen test for screening of both symptomatic and asymptomatic individuals, infected or suspected of being infected with the COVID-19 virus. Therma Bright will control 50% of Torion with the remaining 50% controlled...

    2020-11-04 5:00 PM ET
  • Therma Bright and Orpheus Medica Advance CoviSafe(TM) Rapid Saliva Test to Formal Product Developmental Phase

    Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the successful completion of the initial feasibility studies with its polypeptide detection candidates for CoviSafe™. Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc. ("nanoComposix") to complete the development of CoviSafe™. NanoComposix is uniquely positioned to begin final development of...

    2020-10-21 6:15 PM ET
  • Therma Bright und Orpheus Medica sichern Mitacs-Finanzierung zur Unterstützung ihres Forschungs- und Entwicklungsprogramms für COVID-19

    Toronto, Ontario--(Newsfile Corp. - Freitag, 9. Oktober 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, und sein Mitentwicklungspartner, Orpheus Medica Inc. ("Orpheus") freuen sich über die Bewilligung eines "Mitacs Elevate"-Forschungspraktikumsprogramms. Der Projektantrag unterlief eine Peer-Review. Ende September wurden Matching-Mittel für ein Postdoktorandenstipendium bewilligt.Therma und Orpheus führen derzeit Machbarkeitstests von CoviSafe™ durch. Zusätzliche biologische Moleküle werden nun unserer Screening-Plattform hinzugefügt. Damit füllen wir möglicherweise die Lücke in den derzeitigen Screening-Methoden zum Nachweis des COVID-19-Virus...

    2020-10-09 9:20 AM ET